MEIJI-SEIKA-PHARMA/FBRI
16.1.2023 06:01:39 CET | Business Wire | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) and the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan, President: Tasuku Honjo, hereinafter ‘FBRI’) announce the discovery of a novel anti-PD-1 agonist monoclonal antibody, which can induce immunosuppressive effect, through their collaborative research on “Treatment of inflammatory diseases, including autoimmune diseases, through the immunosuppressive activity of PD-1” (HBI* Innovation Program) conducted at the FBRI's Dept. of Immunology, Institute of Biomedical Research and Innovation (Professor: Akio Ohta). Part of the findings from the above research was published in "Science Immunology**" issued on January 13, 2023 (Eastern Standard Time). For more information, please visit the FBRI website (URL: https://www.fbri-kobe.org/kbic/english/pressrelease/2023_01-16/).
Meiji Seika Pharma and FBRI are working together to develop the above PD-1 agonist monoclonal antibody as therapeutic candidate for autoimmune diseases.
PD-1 is a molecule expressed on activated lymphocytes and has the function as a suppressor of immune responses. Antibodies that inhibit the function of PD-1 (anti-PD-1 blocking antibodies) can enhance anti-tumor immunity, so that they have been applied to cancer treatment as "immune checkpoint inhibitors."
Through the above joint research supervised by Program Director Tasuku Honjo, Nobel laureate in 2018, Meiji Seika Pharma and FBRI discovered the conditions necessary for inducing immunosuppression by stimulating the function of PD-1 with antibodies. "Anti-PD-1 agonist antibody" is expected to be applied as a novel therapeutic for inflammatory diseases such as autoimmune diseases caused by excessive immune reactions.
Meiji Seika Pharma and FBRI continue to progress the joint research on "anti-PD-1 agonist antibody" and strive to the early contribution of this antibody as a therapeutic agent for autoimmune diseases.
*: HBI: Honjo Kobe Research Center for Biomedical Innovation
**: DOI: 10.1126/sciimmunol.add4947
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230115005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ThetaRay Gamifies Financial Defense at Money20/20 Europe with a Compliance Twist on “Where’s Waldo”2.6.2026 09:30:00 CEST | Press release
With “Spot The Money Mule”, ThetaRay unites Agentic AI and public education to disrupt criminal recruitment; pushing for an ecosystem-wide stand against illicit finance. ThetaRay, a leader in AI infrastructure for financial crime compliance, today unveiledSpot The Money Mule at Money20/20 Europe. The high-speed online game is a compliance twist on "Where’s Waldo" for the AI age, designed to bridge the gap between complex banking infrastructure and the public’s role in stopping global crime. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602629234/en/ The game challenges players to find a money mule hidden in plain sight across five buzzing everyday scenes, from the morning rush at an airport to the vibrant rows of a Dutch Tulip Festival. “In the AI age, the most dangerous threats are those that blend perfectly into the speed of our digital lives,” said Garima Chaudhary, VP Financial Crime & Compliance AI at ThetaRay. “In
The Open Group Launches the Open Footprint® Standard, Edition 1.0 to Streamline Scope 1, 2, and 3 Emissions Management2.6.2026 09:00:00 CEST | Press release
The Open Group, the vendor-neutral technology and standards organization, today announced the release of the Open Footprint® Standard, Edition 1.0, that will help organizations streamline scope 1, 2, and 3 emissions reporting. The new standard is the first open emissions data model to address all three scopes, providing a comprehensive framework that enables organizations to collect and standardize data from their value chain and report across multiple jurisdictions. “There is an urgent need to streamline emissions data management and reduce the manual effort required to capture data within supply chains, perform data conversion, and report out to various regulators,” said Steve Nunn, President and CEO of The Open Group. “The Open Footprint Standard removes friction and lowers cost, helping organizations identify emissions reduction opportunities.” Key features of the model include: Standardized emissions data definitions and relationships Simplified emissions data sharing and interope
Thredd Renews and Expands Partnership with Caxton2.6.2026 09:00:00 CEST | Press release
Five-year renewal and strategic expansion strengthens travel, corporate, and parent-child card innovation Thredd, the AI-first issuer processing platform, today announced a five-year renewal and strategic programme expansion with Caxton, the leading payments solutions provider, reinforcing Thredd’s role as the company’s primary issuer-processor across consumer and corporate cards. Caxton, a leading UK payments provider, has partnered with Thredd since 2020 to power its multi-currency prepaid travel and expense cards. Customers can hold up to 15 currencies on a single card. As part of the renewed agreement, Thredd will bring Caxton’s parent-child card programme, nimbl, onto the Thredd platform. All nimbl customers will be re-carded as the programme is launched using Thredd’s infrastructure, with completion targeted before the end of the year. nimbl is a financial education-focused debit card designed for children aged 6–16, enabling parents to manage allowances and teach money managemen
Medscape Brings AI to the Hematology Frontline at EHA 20262.6.2026 08:00:00 CEST | Press release
Landmark symposium to equip clinicians with practical, ethical AI frameworks, chaired by a lead author of Europe's ESMO EBAI and ELCAP oncology guidelines. Medscape Education will launch Future-Ready Hematologists: Practical and Ethical Use of AI in Hematology and Oncology at EHA 2026 on June 11, where leading experts will convene to explore responsible AI in one of medicine's most complex, rapidly evolving specialties. Registration is free for all EHA delegates. Reserve your seat here. The session is chaired by Prof. Jakob N. Kather, MD, MSc, Else Kroener Fresenius Center for Digital Health, Technical University Dresden, and NCT, University Hospital Heidelberg. He is joined by Prof. Chan Cheah, MBBS, DMSc, Consultant Hematologist, Sir Charles Gairdner Hospital, Perth, Australia; and Prof. Matthew Lunning, DO, FACP, Chief of Hematology and Assistant Vice Chancellor of Research, University of Nebraska Medical Center. Hematology moves faster than any clinician can track alone. AI can clo
Signaloid Announces Preview of New ASIC Targeted at Physical AI and Robotics Applications2.6.2026 06:00:00 CEST | Press release
Signaloid previews a new ASIC purpose-built for physical AI and robotics workloads.The chip, taped out with TSMC in partnership with IC-Link by imec and Cadence, is projected to deliver up to 1000× better performance-per-watt in key physical AI workloads. Signaloid (https://signaloid.com), a computing platform company providing hardware and binary-translation-based acceleration of AI, robotics, aerospace, and quantitative finance workloads, today announced the tapeout and preliminary specifications documents for its C0-ASIC. Delivery of engineering samples to the first customer is due in Q3 2026 and additional FPGA-based systems implementing the ASIC’s design are under discussion for deployment in the UK and Switzerland later in 2026. The C0-ASIC was targeted specifically at energy-efficient physical AI workloads. The UK Advanced Research and Invention Agency (ARIA) will take delivery of systems based on the ASIC for use in next-generation AI workloads such as second order methods. “Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom